Human anti-TNF antibodies and peptides
AssigneesCentocor, Inc., New York University
InventorsJunming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Claims28
An isolated recombinant anti-TNFα antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF-α, and (ii) binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF decapeptide pins which overlap at every second amino acid.
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF-α, and (ii) binds to at least one epitope included in amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO:1 of hTNF, as determined by Geysen epitope mapping comprising use of TNF dodecapeptide pins which overlap at every second amino acid.
An isolated recombinant anti-TNFα antibody or antigen-binding fragment thereof, comprising a human constant region, wherein said antibody or antigen-binding fragment comprises A2 (ATCC Accession No. PTA-7045).
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen-binding fragment (i) has epitopic specificity identical to A2 (ATCC Accession No. PTA-7045), and (ii) binds to a neutralizing epitope of human TNF-α in vivo with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen binding fragment competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF-α.
An isolated nucleic acid comprising a nucleotide sequence encoding a recombinant antibody light chain that specifically binds human TNFα and competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF-α, said light chain comprising a human light chain constant region and a human light chain framework region, wherein said human light chain binds to a neutralizing epitope of human TNF-α in vivo with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
An isolated nucleic acid comprising a nucleotide sequence encoding a recombinant antibody heavy chain that specifically binds human TNFα and competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF-α, said heavy chain comprising a human heavy chain constant region and a human heavy chain framework region, wherein said heavy chain binds to a neutralizing epitope of human TNF-α in vivo with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
Dependencies are inferred from the claim text.